Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dangerously high triglyceride (fat) levels.

IONS shares are retreating from recent levels. See if it is worth your attention here

The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) levels of up to 72% at six months.

The reductions were sustained through 12 months. Olezarsen showed a highly statistically significant 85% reduction in acute pancreatitis events.

Additionally, 86% of olezarsen-treated patients achieved triglyceride levels less than 500 mg/dL, below the risk threshold for acute pancreatitis, sudden inflammation of the pancreas.

Also Read: Ionis Pharmaceuticals Reveals ‘Unprecedented Results’ From Rare Neurological Disease Trial

Olezarsen demonstrated favorable safety and tolerability.

These data were presented at the American Heart Association (AHA) ...